[Selective inhibition of T-cell activation with fusion protein CTLA4lg as a new treatment option for rheumatoid arthritis].
Krüger
K
K
St.-Bonifatius-Str. 5, 81541, München, Germany. klaus.krueger@medinn.med.uni-muenchen.de
D000069594:Abatacept; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000097:blood; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D038622:Internationality; D008213:Lymphocyte Activation / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology
D000906:Antibodies; D018796:Immunoconjugates; D000069594:Abatacept